MOG (35-55): Gold Standard Peptide for Experimental Autoimmune Encephalomyelitis Modeling

Executive Summary: MOG (35-55), a truncated peptide from human myelin oligodendrocyte glycoprotein, is the most widely used inducer for experimental autoimmune encephalomyelitis (EAE) in murine models of multiple sclerosis (MS) (Xu et al., 2025). The peptide, corresponding to amino acids 35–55, reliably induces robust T and B cell immune responses when administered with complete Freund's adjuvant (CFA) (APExBIO, A8306). In vivo, dosing between 50–150 μg per mouse results in reproducible MS-like symptoms and weight loss, with severity scaling by dose. In vitro, MOG (35-55) increases NADPH oxidase and MMP-9 activity, implicating oxidative stress and matrix remodeling in pathogenesis. The peptide is a critical tool for dissecting neuroinflammation and evaluating therapeutic interventions in MS research.

Biological Rationale

Myelin oligodendrocyte glycoprotein (MOG) is a member of the immunoglobulin superfamily, predominantly localized on the outermost lamellae of central nervous system (CNS) myelin. The MOG (35-55) peptide, corresponding to residues 35–55 of the human MOG protein, is immunodominant in the C57BL/6 mouse strain and several HLA-DR2-transgenic models (APExBIO, A8306). When introduced with CFA, it triggers a cascade of autoimmune responses that closely recapitulate the clinical and histopathological features of human multiple sclerosis, including relapsing-remitting neurological deficits and demyelinating plaques (Article: The Gold Standard Peptide for Experimental A...). This model is central for examining both the induction and regulation of autoimmunity in the CNS. While previous reviews have focused on protocol optimization, this article provides mechanistic updates and integrates emerging evidence on interferon signaling modulation (Translating Mechanistic Insights...).

Mechanism of Action of MOG (35-55)

MOG (35-55) acts as an encephalitogenic epitope. Upon subcutaneous injection with CFA, antigen-presenting cells process and present the peptide on MHC class II molecules, activating myelin-specific CD4+ T cells (Xu et al., 2025). This leads to the recruitment of B cells and the generation of anti-MOG autoantibodies. The immune response is characterized by perivascular infiltration of T and B lymphocytes, activation of microglia, and local production of pro-inflammatory cytokines. Subsequent demyelination is mediated by both cellular and humoral mechanisms. MOG (35-55) also increases NADPH oxidase activity, resulting in elevated reactive oxygen species (ROS) and further tissue damage. Matrix metalloproteinase-9 (MMP-9) is upregulated, facilitating blood-brain barrier disruption and leukocyte migration into the CNS. The EAE model induced by MOG (35-55) thus mirrors essential aspects of MS pathophysiology.

Evidence & Benchmarks

• MOG (35-55) (A8306) reliably induces severe, chronic EAE in C57BL/6 and HLA-DR2-transgenic mice when administered subcutaneously at 50–150 μg with CFA (Xu et al., 2025, https://doi.org/10.1016/j.celrep.2025.116130).
• Peptide solubility is ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO; it is insoluble in ethanol, ensuring formulation specificity (APExBIO, product page).
• Dose-dependent induction of weight loss and neurological symptoms is observed within 10–14 days post-injection (Reliable EAE Induction, internal article).
• In vitro, exposure to MOG (35-55) increases NADPH oxidase and MMP-9 activity, consistent with enhanced oxidative stress and matrix remodeling (Xu et al., 2025, DOI).
• PARP7 inhibition in MOG (35-55)-induced EAE stabilizes STAT1/STAT2 and mitigates disease severity, highlighting a regulatory axis relevant to MS (Xu et al., 2025, DOI).

Applications, Limits & Misconceptions

MOG (35-55) is the gold standard for EAE induction in murine MS research, enabling study of neuroinflammation, T/B cell responses, and therapeutic interventions. It is also suitable for evaluating immunomodulatory compounds targeting interferon signaling, such as PARP7 inhibitors. However, several boundaries must be clarified.

Common Pitfalls or Misconceptions

• MOG (35-55) does not induce EAE in all mouse strains; susceptibility is largely limited to C57BL/6 and HLA-DR2-transgenic backgrounds.
• Solubility in ethanol is poor; using ethanol as a solvent leads to precipitation and assay failure (APExBIO).
• Peptide must be freshly prepared and stored at -20°C in a desiccated state to prevent degradation; repeated freeze-thaw cycles diminish potency.
• Clinical scores and weight loss are dose-dependent; suboptimal dosing may yield incomplete or inconsistent disease phenotypes.
• The model does not fully recapitulate all aspects of human MS, such as primary progressive forms or complex environmental triggers.

This article expands upon prior protocol-focused reviews (Reliable EAE Induction) by integrating recent mechanistic insights, including the impact of STAT1/STAT2 regulation by PARP7 (Xu et al., 2025), and providing explicit solubility, dosing, and workflow guidance.

Workflow Integration & Parameters

• For experimental use, prepare MOG (35-55) stock solutions in sterile water at 0.50 mg/mL; warming and ultrasonic bath treatment may improve solubility (APExBIO).
• Store aliquots desiccated at -20°C; avoid repeated freeze-thaw cycles.
• Administer 50–150 μg per mouse (subcutaneous), emulsified in CFA, to induce EAE within 10–14 days.
• Monitor mice daily for neurological scores and weight loss; adjust dosing based on strain-specific sensitivity.
• For in vitro assays, MOG (35-55) is soluble up to 32.25 mg/mL (water) and 86 mg/mL (DMSO). Avoid ethanol.

For protocol optimization and troubleshooting, see scenario-driven guidance in Reliable EAE Induction (extends with practical dosing/solubility details) and MOG (35-55): The Gold Standard Peptide... (clarifies mechanistic fidelity and reproducibility).

Conclusion & Outlook

MOG (35-55) remains the benchmark peptide for EAE induction and MS modeling, enabling reproducible induction of neuroinflammation and T/B cell-mediated autoimmunity. Recent advances implicate type I interferon signaling and PARP7-mediated STAT1/STAT2 degradation as critical regulators of EAE severity, offering new therapeutic targets (Xu et al., 2025). APExBIO’s MOG (35-55) (A8306) combines high solubility, batch-to-batch consistency, and validated protocols, supporting advanced research in neuroimmunology. Future directions include integrating single-cell and omics approaches to dissect immune heterogeneity and testing novel modulators of the interferon axis. For authoritative product and protocol details, see MOG (35-55) product page.